Systemic Sclerosis Treatment Market Forecasted to Reach USD 2.2 Billion by 2033 at a 7.9% CAGR

Systemic Sclerosis Treatment Market

The global systemic sclerosis treatment market has reached a valuation of US$ 928.1 million in 2022, with robust growth projected in the coming years. According to Future Market Insights, the market is expected to grow at a compound annual growth rate (CAGR) of 7.9%, attaining a valuation of US$ 2.2 billion by the end of 2033. Currently, drug therapies dominate this market, capturing an impressive 95.4% share in 2022.

Systemic sclerosis, a rare autoimmune disorder affecting connective tissues, continues to have a high unmet medical need, driving the demand for effective treatments. Drug therapies, primarily immunosuppressants and antifibrotics, have become essential in managing the progression and symptoms of systemic sclerosis, thereby contributing significantly to market growth.

The focus on advanced drug therapies is leading to an increase in research and development (R&D) initiatives, with pharmaceutical companies prioritizing treatments aimed at improving patient outcomes. Innovations in drug development, especially in targeted biologics and novel immunotherapies, are anticipated to provide improved therapeutic options and are likely to fuel market expansion over the forecast period.

Beyond drug therapies, there is a growing interest in complementary treatment options, including lifestyle modifications and supportive care, which further highlights the need for comprehensive disease management solutions. However, the significant reliance on drug therapy underscores its continued dominance and critical role within the systemic sclerosis treatment landscape.

Systemic sclerosis, also known as scleroderma, is a chronic autoimmune disease characterized by fibrosis and vascular abnormalities. The prevalence of systemic sclerosis is increasing globally, driving the demand for effective treatment options. As awareness and diagnosis of the disease improve, the market for systemic sclerosis treatments is expected to expand. The introduction of these emerging therapies expands the market and offers hope for improved disease management.

The systemic sclerosis treatment market is expanding in emerging economies due to improving healthcare infrastructure, rising healthcare expenditure, and increased access to specialized care. This expansion presents growth opportunities for systemic sclerosis treatment providers and pharmaceutical companies.

What are the Factors Influencing the Demand for Systemic Sclerosis Treatment?

The increasing prevalence of systemic scleroderma worldwide can be attributed to a variety of factors, including genetics, environmental factors, immune system dysfunction, and other factors.

The severity and progression of systemic sclerosis vary among individuals. Patients with more severe symptoms, organ involvement, or rapid disease progression require more intensive treatment regimens. The demand for systemic sclerosis treatment is higher among patients with advanced stages of the disease or those experiencing significant symptoms and complications.

The range of available treatment options plays a significant role in determining demand. Patients and healthcare professionals seek diverse therapeutic choices to address the complex nature of systemic sclerosis. The availability of disease-modifying therapies, immunosuppressants, vasodilators, and supportive care interventions influences the demand for systemic sclerosis treatment.

It has been observed that genetic factors may contribute to the vulnerability of individuals towards autoimmune diseases. There exists a correlation between specific genes and an elevated likelihood of systemic scleroderma. With the advancement of genetic studies, a greater number of individuals with a genetic predisposition may be identified, which could potentially lead to an increase in prevalence rates.

Hence, the global systemic scleroderma treatment market is being driven by the high prevalence and incidence rate of the disease worldwide.

Competition Landscape

The market for systemic sclerosis treatment has a fair amount of competition. The key players in the market are also putting a lot of effort into expanding their presence in emerging markets with new partnerships and merger acquisitions also focusing on launching new technologically advanced products. The competitive environment includes an analysis of a few global and local businesses that control the market shares. Along with acquisitions and mergers and partnerships with key market players.

Some key instances of development include:

• In March 2021, Janssen Pharmaceutical, a company of Johnson & Johnson received approval from USA Food and Drug Administration (FDA) for PONVORY (ponesimod) for the treatment of multiple sclerosis.
• In March 2021, Genentech received approval from the USA (FDA) for Actemra (tocilizumab) subcutaneous injection for the treatment of systemic sclerosis-associated interstitial lung disease.

Similarly, the team at Future Market Insights has tracked recent developments related to companies in the systemic sclerosis treatment market, which are available in the full report.

Key Companies Covered

Medtronic Plc; GlaxoSmithKline Plc; Lupin Ltd; Johnson & Johnson Services Inc.; Bayer Healthcare LLC; F. Hoffmann-La Roche Ltd; Amgen Inc; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Zydus Lifescience Ltd.; Organon LLC; Accord Healthcare Inc.; Pfizer, Inc.; Sanofi S.A.; Cipla Ltd.

A Comprehensive Full Report

Key Segments Covered in Systemic Sclerosis Treatment Market

By Therapeutics:

• By Drug Therapy
  • Corticosteroids
  • Immunosuppressants
  • Nonsteroidal Anti-Inflammatory Drugs
  • Blood Pressure Medication
  • Proton Pump Inhibitors
  • TNF Inhibitors
  • Light Therapy
  • Nitroglycerin Ointment
  • Others
• Hematopoietic Stem Cell Transplantation (HSCT)

By Indication:

• Limited Cutaneous Systemic Sclerosis Lamotrigine
• Diffuse Cutaneous Systemic Sclerosis

By Target Organ:

• Skin Fibrosis
• Musculoskeletal
• Digital Ulcers
• Pulmonary Arterial Hypertension
• Gastrointestinal
• Pulmonary Fibrosis
• Scleroderma Renal Crisis

By Route of Administration:

• Injectable
• Oral
• Topical

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa